Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
11 studies found for:    DIPAK
Show Display Options
Rank Status Study
1 Active, not recruiting Study of Lanreotide to Treat Polycystic Kidney Disease
Condition: Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Intervention: Drug: Lanreotide
2 Recruiting Use of EBUS TBNA for Cell Culture as an Aid to Diagnose Lung Cancer and Lymphoma
Conditions: Lung Cancer;   Lymphoma;   Non-small Cell Lung Cancer;   Non-Hodgkin Lymphoma;   Mediastinal Lymphadenopathy
Intervention: Other: Cohort
3 Not yet recruiting Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)
Condition: Permanent Atrial Fibrillation
Interventions: Drug: Bisoprolol;   Drug: Digoxin
4 Not yet recruiting WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW - ACS)
Condition: Acute Coronary Syndrome
Intervention: Drug: Aspirin
5 Recruiting Cardiovascular Longitudinal Evaluation & Assessment of Risk (CLEAR) Study
Condition: Cardiovascular Disease
Intervention:
6 Enrolling by invitation Collaborative Systematic Overview of Randomised Controlled Trials of Beta-Blockers in the Treatment of Heart Failure
Condition: Heart Failure
Interventions: Drug: Beta blocker;   Other: Placebo
7 Terminated A Study to Evaluate the Safety and Efficacy of the QLT Proprietary Olopatadine-PPDS in Subjects With Seasonal Allergic Conjunctivitis to Ragweed in an Environmental Exposure Chamber Model.
Condition: Seasonal Allergic Conjunctivitis to Ragweed
Intervention: Drug: Olopatadine
8 Active, not recruiting Alternative Risk Markers in Coronary Artery Disease (ARMCAD)
Condition: Coronary Artery Disease
Intervention:
9 Recruiting To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel
Condition: Acne Vulgaris
Interventions: Drug: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel;   Drug: DUAC® Gel;   Drug: Placebo
10 Recruiting Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer.
Intervention: Drug: ceritinib
11 Recruiting A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Interventions: Drug: RRx-001;   Drug: Regorafenib;   Drug: Irinotecan

Indicates status has not been verified in more than two years